Bio-Rad Laboratories (BIO) FY 2025 Conference September 04, 2025 12:45 PM ET Company ParticipantsBrandon Couillard - Managing DirectorRoop Lakkaraju - Executive VP & CFONorman Schwartz - Chairman & CEOBrandon CouillardGood afternoon. Welcome to the Wells Fargo Healthcare Conference. Thanks for being here. I'm Brandon Couillard. I cover life science tools and diagnostics sector here at the firm.It's a real treat to have Bio Rad with us back at the conference this year. Joining me for this conversation to my ...

Avidity Biosciences (RNA) FY 2025 Conference September 04, 2025 12:45 PM ET Company ParticipantsKathleen Gallagher - Chief Program OfficerMichael MacLean - CFOConference Call ParticipantsYanan Zhu - Senior Analyst - Biotechnology Equity ResearchYanan ZhuGreat. Thanks, everyone, for being here. My name is Yan Andriu. I'm one of the biotech analysts here at Wells Fargo. It is our great privilege to have the Avidity Biosciences management team here for Fireside Chat. With me on stage, CFO Mike MacLean and Kath ...

Prestige Consumer Healthcare (PBH) FY 2025 Conference September 04, 2025 12:45 PM ET Speaker0Everyone. Thanks for joining us. I'm Ron Lombardi, chairman and CEO of Prestige Consumer Health Care, joined by Christine Sacco, our chief operating and financial officer. So today, we're gonna give an update and talk a bit about our business. I'll start things off, and I'll turn it over to Chris who'll who'll wrap up today's discussion.So with that, let's jump into the the slide that I always like to to present and ...

Bio-Rad Laboratories (BIO) FY 2025 Conference September 04, 2025 12:45 PM ET Speaker0Good afternoon. Welcome to the Wells Fargo Healthcare Conference. Thanks for being here. I'm Brandon Couillard. I cover life science tools and diagnostics sector here at the firm.It's a real treat to have Bio Rad with us back at the conference this year. Joining me for this conversation to my left, CFO, Roop Lakaraju and CEO, Doran Schwartz. Thank you both for being here.Speaker1Thanks for having us.Speaker0Maybe this would ...

Bio-Rad Laboratories (BIO) FY 2025 Conference September 04, 2025 12:45 PM ET Speaker0All right. Good afternoon. Welcome to the Wells Fargo Health Care Conference. Thanks for being here. I'm Brandon Coulliard. I cover life science tools and diagnostics sector here at the firm. It's a real treat to have Bio-Rad Laboratories with us back at the conference this year. Joining me for this conversation, to my left, CFO Roop Lakkaraju.Thank you. CEO Norman Schwartz, thank you both for being here.Speaker2Thanks for ...

Avidity Biosciences (RNA) FY 2025 Conference September 04, 2025 12:45 PM ET Speaker0Great. Thanks, everyone, for being here. My name is Yan Andriu. I'm one of the biotech analysts here at Wells Fargo. It is our great privilege to have the Avidity Biosciences management team here for Fireside Chat. With me on stage, CFO Mike MacLean and Kath Gallagher, Program Manager for the Muscle Disease Programs. Thank you for being here.Speaker2Thank you, Yan.Speaker0Great. I was wondering if, Mike, could you provide an ...

Financial Data and Key Metrics Changes - Merck is in a transformation phase with a diversified set of growth drivers, aiming for over $50 billion in revenues by the mid-2030s from its pipeline [3][4] - The company is launching 20 products, most of which have blockbuster potential [3][4] Business Line Data and Key Metrics Changes - KEYTRUDA continues to show strong growth with 42 approved indications in the U.S. across 18 tumor types, with expectations for continued growth from new indications [6][7] - The subcutaneous formulation of KEYTRUDA is anticipated to achieve 30% to 40% adoption within 18 to 24 months post-launch [9][11] Market Data and Key Metrics Changes - The company is well-positioned to manage the impact of tariffs and has a diverse supply chain footprint [41][42] - The impact of the Most Favored Nation (MFN) policy is expected to be manageable, as it only accounts for less than 10% of revenues [42][43] Company Strategy and Development Direction - Merck is focused on innovation and expanding its pipeline, with plans to increase R&D investments due to a strong pipeline of 80 Phase III clinical programs [51][52] - Business development remains a priority, with a focus on bringing in innovative science that addresses unmet medical needs [67][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the loss of exclusivity for KEYTRUDA and emphasized the importance of their pipeline in driving future growth [5][6] - The company is optimistic about the readouts from its oncology and HIV pipelines in the coming year [80][81] Other Important Information - The company is preparing for the launch of its oral PCSK9 inhibitor, which is expected to democratize access to this treatment [60][62] - Merck is also excited about its cancer vaccine program, focusing on early-stage cancers with potential curative opportunities [39][40] Q&A Session Summary Question: What are the growth avenues for KEYTRUDA? - Management expects continued growth from new indications, including early-stage lung cancer and women's cancers [7][8] Question: How will the adoption of the subcutaneous formulation of KEYTRUDA be affected? - Factors such as pricing, access, and the J code will influence adoption rates, with expectations of 30% to 40% adoption within 18 to 24 months [10][11] Question: What is the confidence level in the TROP-two ADC program? - Management expressed confidence based on early signals and extensive clinical trials, highlighting its unique properties and potential in maintenance settings [17][18] Question: How does Merck plan to address macroeconomic headwinds like tariffs? - The company has a diverse supply chain and is well-positioned to manage tariff impacts, focusing on innovation and product launches [41][42] Question: What is the outlook for Gardasil in China? - Gardasil is not expected to drive significant growth in China, with future growth anticipated from international markets and new product launches [69][70] Question: What are the expectations for the cancer vaccine program? - The program is focused on early-stage cancers, with positive readouts expected in the next couple of years [39][40]

Financial Data and Key Metrics Changes - The company is in a transformation phase with a diversified set of growth drivers, expecting over $50 billion in revenues by the mid-2030s from its pipeline [3][4][5] - The company is launching 20 products, most of which have blockbuster potential [3][4] Business Line Data and Key Metrics Changes - KEYTRUDA continues to show strong growth with 42 approved indications across 18 tumor types, with new indications expected to drive future growth [6][7][8] - The subcutaneous formulation of KEYTRUDA is anticipated to achieve 30% to 40% adoption within 18 to 24 months post-launch [9][11] - The company has 24 oncology assets in clinical trials, focusing on immune stimulation, chemotherapy improvements, and specific targeting agents [13][15] Market Data and Key Metrics Changes - The company is well-positioned to manage tariff impacts due to a diverse supply chain and manufacturing footprint [42][43] - The impact of the Most Favored Nation (MFN) policy is expected to be manageable, with less than 10% of revenues affected [43][44] Company Strategy and Development Direction - The company is focused on innovation and expanding its pipeline, with a commitment to reinvest $3 billion in annual cost savings into R&D [51][52] - Business development remains a priority, with a focus on bringing in innovative science that addresses unmet medical needs [66][67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the loss of exclusivity for KEYTRUDA and emphasized the importance of new product launches [5][6] - The company is optimistic about the future, with expectations for positive readouts from its pipeline and successful product launches [78][79] Other Important Information - The company is excited about the potential of its oral PCSK9 inhibitor, which showed a 60% reduction in LDL cholesterol in Phase II trials [59][60] - The company is also exploring opportunities in the GLP-1 space, with an oral formulation expected to enter Phase I trials [62][64] Q&A Session Summary Question: What are the growth avenues for KEYTRUDA? - Management highlighted new indications in lung cancer and women's cancers as key growth opportunities [6][7] Question: How does the company plan to handle tariff impacts? - The company has a diverse supply chain and believes the impact of tariffs is manageable [42][43] Question: What is the strategy for the new PD-1 VEGF bispecifics? - The company is focusing on specific patient strata and therapeutic indications to differentiate from existing treatments [32][33] Question: How will the company approach pricing in light of MFN? - The company plans to price products based on the value they bring, ensuring broad access while being mindful of MFN implications [44][46] Question: What is the outlook for the cancer vaccine program? - Management is optimistic about the enthusiasm from investigators and the potential for early-stage cancer treatments [39][40] Question: How does the company view the future of Gardasil in China? - Gardasil is not expected to drive significant growth in China, with focus shifting to international markets [68][69]

Valvoline (VVV) FY 2025 Conference September 04, 2025 11:40 AM ET Company ParticipantsMark Jordan - VP - Equity ResearchLori Flees - CEO & DirectorKevin Willis - CFOMark JordanOkay. Good morning, everyone. My name is Mark Jordan. I'm an analyst here at Goldman Sachs. Thank you very much for joining us today at the Goldman Sachs thirty second Annual Global Retailing Conference.It's my pleasure to introduce Valvoline and to moderate our fireside chat. Today, we have with us here Lori Fleas, Chief Executive Of ...

DICK’S Sporting Goods (DKS) FY 2025 Conference September 04, 2025 11:40 AM ET Company ParticipantsKate McShane - Managing DirectorEdward Stack - Executive ChairmanLauren Hobart - Director, President & CEONavdeep Gupta - Executive VP & CFOKate McShaneGood morning. It's my pleasure to introduce DICK'S Sporting Goods and to moderate our fireside chat. Today, we have with us Ed Stack, executive chairman of DICK'S Sporting Goods. We have Lauren Lauren Hobart, president and chief executive. Lauren joined DICK'S i ...